herpes-zoster

Documents about herpes-zoster

• Associations of herpes zoster disease perceptions, altruism and family harmony with herpes zoster vaccination uptake among older adults in Shenzhen, China.#678156NCBI PubMed Central
• Herpes zoster as a vaccine-preventable risk factor increases the risk of dementia: A nested case-control study in Chinese population#478546Europe PMC
• Immune Response to Varicella-Zoster Vaccination and Infection#1031127ClinicalTrials.gov
• Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster#1032374ClinicalTrials.gov
• The real-world economic impact of herpes zoster disease in patients with selected underlying conditions in Spain.#9921PubMed
• Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers#307304ClinicalTrials.gov
• Incidence and factors associated with Herpes Zoster infection in kidney transplant recipients, a recent epidemiological study#330285HAL (France)
• A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults#849125ClinicalTrials.gov
• A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years#414340ClinicalTrials.gov
• The real-world economic impact of herpes zoster disease in patients with selected underlying conditions in Spain#5140Europe PMC
• Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster#851153ClinicalTrials.gov
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age#992948ClinicalTrials.gov
• Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection#881760ClinicalTrials.gov
• Shingles Prevention Study#329561ClinicalTrials.gov
• A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)#125914ClinicalTrials.gov
• Herpes zoster in children during the COVID-19 pandemic in France: A retrospective multicenter observational study#147459HAL (France)
• Age-group differential trends in the incidence of herpes zoster during 2010-2024 using Korean national healthcare claim data#253538Europe PMC
• From awareness to action: Overcoming knowledge gaps and enhancing herpes zoster vaccination counseling among Chinese rheumatologists - Results from a nationwide survey#273240Europe PMC
• Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over#373651ClinicalTrials.gov
• Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers#387211ClinicalTrials.gov
• The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)#896913ClinicalTrials.gov
• Herpes zoster vaccination among older adults in urban China: A mixed-methods study in Shenzhen#5092Europe PMC
• ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)#966504ClinicalTrials.gov
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier#623544ClinicalTrials.gov
• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older#383603ClinicalTrials.gov
• Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age#414367ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)#459956ClinicalTrials.gov
• Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation#847649ClinicalTrials.gov
• Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years#902133ClinicalTrials.gov
• Shingles: Immune Effects of Tai Chi#141083ClinicalTrials.gov
• Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia#968196ClinicalTrials.gov
• Association between COVID-19 vaccines and herpes zoster and urticaria: a UK population-based self-controlled case series study#477534University of Nottingham Repository
• A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems#833728ClinicalTrials.gov
• Herpes zoster vaccination and cognitive disorders in older adults.#28216NCBI PubMed Central
• ZOSTAVAX® in Renal Transplant Patients#143632ClinicalTrials.gov
• Quantitative study of the knowledge, attitudes, and practices (KAP) towards herpes zoster (HZ) and HZ vaccination: Survey findings from a multi-country study in Asia (ZOASIS)#5146Europe PMC
• Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study#450664S-Space: Seoul National University
• Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo#905037ClinicalTrials.gov
• Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above#217114ClinicalTrials.gov
• Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above#307302ClinicalTrials.gov
• Association between vaccination prescription program and herpes zoster vaccine knowledge, intention, and coverage among residents aged ≥50 in Zhejiang Province: Repeated cross-sectional surveys#5108Europe PMC
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older#141074ClinicalTrials.gov
• A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older#325132ClinicalTrials.gov
• Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)#906112ClinicalTrials.gov
• ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)#279581ClinicalTrials.gov
• Enhancing a Sustainable Pharmacy-based Immunization Program in Two States#332798ClinicalTrials.gov
• ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)#332801ClinicalTrials.gov
• Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older#363647ClinicalTrials.gov
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant#911065ClinicalTrials.gov
• Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia#321557ClinicalTrials.gov